ACUTE LEUKEMIAS &MYELOPROLIFERATIVE NEOPLASMS

WESTIN AT LAS COLINAS | IRVING, TX

Expert Forum on

FEB 28-29,2020

RICHARD STONE, MD Harvard Medical School

Dana-Farber Cancer InstituteBoston, MA

EUNICE WANG, MDChief, Leukemia Service

Roswell Park Cancer InstituteBuffalo, NY

CHAIRS

FEB 28-29, 2020 | DALLAS, TX

Expert Forum onACUTE LEUKEMIAS & MYELOPROLIFERATIVE NEOPLASMS

FACULTY CLARA D. BLOOMFIELD, MDDistinguished University ProfessorThe Ohio State University Comprehensive Cancer Center Columbus, OH

PRITHVIRAJ BOSE, MDAssociate Professor of MedicineUT MD Anderson Cancer CenterHouston, TX

SHENG CAI, MD, PHDInstructorMemorial Sloan Kettering Cancer CenterNew York, NY

NAVAL DAVER, MDAssociate ProfessorUT MD Anderson Cancer CenterHouston, TX

ELIHU H. ESTEY, MD Professor, Division of Hematology, University of Washington School of Medicine (UW)Member Clinical Research Division Fred Hutchinson Cancer Research Center (FHCRC)Director of AML Clinical Research UW and FHCRCSeattle, WA

GUILLERMO GARCIA-MANERO, MDDeputy Chair, Translational Medicine UT MD Anderson Cancer CenterHouston, TX

AARON GOLDBERG, MD, PHDAssistant Attending Physician, Leukemia ServiceMemorial Sloan Kettering Cancer CenterNew York, NY

MARINA KONOPLEVA, MD, PHDProfessorUT MD Anderson Cancer CenterHouston, TX

MARK LEVIS, MD, PHDProfessor of Oncology Johns Hopkins School of MedicineBaltimore, MD

MARK LITZOW, MDHead, Acute Leukemia GroupMayo ClinicRochester, MN

JOHN MASCARENHAS, MDAssociate ProfessorMount Sinai School of MedicineNew York, NY

SOHEIL MESHINCHI, MD, PHDProfessor of MedicineFred Hutchinson Cancer CenterSeattle, WA

NAVEEN PEMMARAJU, MDAssociate ProfessorUT MD Anderson Cancer CenterHouston, TX

KEITH PRATZ, MDDirector of Leukemia ProgramAssociate Professor of MedicineUniversity of PennsylvaniaPhiladelphia, PA

JERRY RADICH, MDProfessorFred Hutchinson Cancer CenterSeattle, WA

FARHAD RAVANDI, MDJaniece and Stephen A. Lasher Professor of MedicineUT MD Anderson Cancer CenterHouston, TX

DAVID RIZZIERI, MDProfessor of Medicine Duke Cancer InstituteDurham, NC

BART SCOTT, MDAssociate ProfessorFred Hutchinson Cancer CenterSeattle, WA

RICHARD STONE, MD CHAIRProfessor of MedicineHarvard Medical SchoolDirector, Translational ResearchAdult Leukemia ProgramDana-Farber Cancer InstituteBoston, MA

KOICHI TAKAHASHI, MDAssistant ProfessorUT MD Anderson Cancer CenterHouston, TX

JEFFREY TYNER, PHDProfessor of MedicineOregon Health Sciences UniversityPortland, OR

EUNICE WANG, MD CHAIRChief, Leukemia ServiceRoswell Park Cancer InstituteBuffalo, NY

JOSHUA ZEIDNER, MDAssistant Professor of MedicineUNC-Chapel HillChapel Hill, NC

Friday, Feburary 28, 2020

4:30 pm Welcome and Introductions

Biology and Genetics of MPN and MDS

4:40 pm Understanding Leukemic Transformation of MPN

Prithviraj Bose

4:50 pm Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia

Jeffrey Tyner

5:00 pm Newer Prognostic Scores in MDS Guillermo Garcia-Manero

5:10 pm DISCUSSION

Biology and Genetics of Acute Leukemias

5:30 pm Personalized Oncology in Acute Myeloid Leukemia (AML): Validation of the Prognostic Value of the Knowledge Bank Approach in Patients (Pts) Treated on Cancer and Leukemia Group B/Alliance Protocols

Clara Bloomfield

5:40 pm How Should We Be Genotyping in 2020? Koichi Takahashi

5:50 pm Identifying Immunogenic Targets in AML Soheil Meshinchi

6:00 pm DISCUSSION

6:20 pm Venetoclax-based Combinations with Targeted Agents

Naval Daver

6:30 pm A Therapeutic Vulnerability for EVI1-high AML

Sheng Cai

6:40 pm Concepts and Methods to Determine Genetic Heterogeneity and MRD in AML

Jerry Radich

6:50 pm DISCUSSION

7:10 pm Transcriptome-based Response Prediction in AML

Soheil Meshinchi

7:20 pm MDM2 Inhibitors in AML Naval Daver

7:30 pm DISCUSSION

8:00 pm ADJOURN TO RECEPTION SPONSORED BY GENENTECH

Saturday, February 29, 2020

7:00 am BREAKFAST

Future of Clinical Trials

8:00 am What is the Right Design for AML Trials in 2020/2021?

Mark Levis

8:15 am Impact of Exclusion Criteria on AML Patients

Elihu Estey

8:25 am MRD in AML: Where is it Going? Aaron Goldberg

8:35 am ALL and the Future Development of Targeted Therapies

Mark Litzow

8:45 am DISCUSSION

Therapeutic Landscape of MPN and MDS

9:00 am Ruxolitinib-based Combination Therapies Prithviraj Bose

9:10 am What to Do After Ruxolitinib Failure Naveen Pemmaraju

9:20 am Novel Bromodomain and Extraterminal Domain Inhibitors (BETi) for MPN and MDS

John Mascarenhas

9:30 am Other Emerging MPN Targets John Mascarenhas

9:40 am New Therapies for MDS Guillermo Garcia-Manero

9:50 am What is Next in MDS: Venetoclax and HMA

Aaron Goldberg

10:00 am DISCUSSION

10:20 am BREAK

Improvements in Chemotherapy and Transplantation

10:30 am Which Patients are “Fit” or “Unfit” for “Intensive” Induction?

Elihu Estey

10:40 am Role of Maintenance Therapy after Allogeneic Transplant for Myeloid Malignancies

Bart Scott

10:50 am Update on the Phase III International Microtransplant in AML Study

David Rizzieri

11:00 am New Combinations with CPX-351 Richard Stone

11:10 am DISCUSSION

Targeting FLT3 in IDH1/2mut AML

11:30 am How Will Gilteritinib be Used Post-Approval?

Keith Pratz

11:40 am Crenolanib Combined with Chemotherapy in FLT3 Mutant AML

Eunice Wang

11:50 am Role of Clonal Evolution in Single-agent FLT3i Resistance

Jeffrey Tyner

12:00 pm What is Next for IDH1/2 Inhibitors? TBD

12:10 pm DISCUSSION

12:30 pm LUNCH

Targeting BCL2 in Acute Leukemias

1:20 pm Novel Venetoclax-based Combinations with Chemotherapy

Richard Stone

1:30 pm New Therapies to Abrogate Venetoclax Resistance in AML

Marina Konopleva

1:40 pm DISCUSSION

Targeted Therapy Strategies for Acute Leukemias

1:50 pm Evaluating Drug Efficacy in AML Richard Stone

2:00 pm Bispecifics in Acute Leukemias Farhad Ravandi

2:10 pm Targeting the Hedgehog Pathway in AML: Glasdegib

Eunice Wang

2:20 pm Investigational Role of CDK9 Inhibitors in AML

Joshua Zeidner

2:30 pm Is There a Role for Maintenance Therapy in AML?

Farhad Ravandi

2:40 pm Novel Targets for AML Eunice Wang

2:50 pm DISCUSSION

3:10 pm BREAK

Immunotherapy for the Treatment of Acute Leukemias

3:20 pm Potential for Targeting Macrophages in AML and CLL

Jeffrey Tyner

3:30 pm Cellular Therapies in Acute Leukemias TBD

3:40 pm Immune Checkpoint-based Approaches in Acute Leukemias

Joshua Zeidner

3:50 pm DISCUSSION

Closing: Moving the Field Forward

4:00 pm What is Next for These Promising Agents? Group Discussion

4:15 pm Optimal AML Trial Designs for 2020/2021 Group Discussion

4:30 pm ADJOURN

O N C O L O G Y M E E T I N G I N N O VAT I O N S

Aryn McKeeamckee@davaonc.com

Jenna Parkerjparker@davaonc.com

Lauren Ritchielritchie@davaonc.com

davaonc.com